ITU Tier 1+ #32: Pharmaceuticals (Kₚharma)

Tier 1+ Pass-1. 5 paper 32 of 45. ITU-derived pharmaceuticals on target + chem + PK + efficacy + safety. Drug pipeline funnel + GLP-1 + AI drug discovery. Defines Kₚharma = -log ρₚharma as the operator-algebraic modular Hamiltonian on Hₜarget ⊗ Hchemistry ⊗ HPK ⊗ Hₑfficacy ⊗ Hₛafety. Kₚharma inherits from KQG via the CLPW 2023 type II crossed-product specialised to this scale. Numerical results. GLP-1 Semaglutide STEP Wegovy + Tirzepatide SURMOUNT 2024 58B; Cobenfy KarXT BMS 2024. 9. 27; Lecanemab + Donanemab 2023/2024; Casgevy CRISPR 2023. 12. 8; AI-discovered Insilico Phase 2a 2024. Topics covered. BIO 2024 pipeline 5. 21% success, GLP-1 58B Wegovy/Zepbound, Cobenfy 2024. 9. 27 first non-D2 antipsychotic 70yr, Lecanemab/Donanemab 2023. 1. 6/2024. 7. 2, Casgevy/Lyfgenia 2023. 12. 8 first CRISPR, AI-discovered drug Insilico 2024, Loyal LOY-002 2024. 11. 26 first lifespan drug, MDMA-AT Lykos REJECTED 2024. 8. 9, IRA 2022. 8 + first 10 negotiated drugs 2024. 8. 15 effective 2026. 45-vertex polytope #32 top couplings: #5 Cancer (0. 95), #7 Psych (0. 95), #27 Microbe (0. 92), #30 Kgenome (0. 92), #6 Aging (0. 92), #26 Chiral (0. 92). Ten falsifiable predictions: Pₐvg=0. 66: arXiv 2026 (0. 90 S), GLP-1 Alzheimer Phase 3 2027 (0. 65 M), AI drug approvals 5+ by 2028 (0. 55 M). Pass-2 roadmap: ~1. 7M: Pharma analytics (600K) + Lean Mathlib (200K) + AI drug + clinical collab (900K). Copyright © 2026 Munehiro Terada / Roboken. Licensed under CC-BY-4. 0.